Analyst Price Targets — QTRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 10:58 am | Kyle Mikson | Canaccord Genuity | $3.00 | $2.59 | StreetInsider | Quanterix Corp. (QTRX) PT Lowered to $3 at Canaccord |
| April 20, 2026 1:02 pm | — | Canaccord Genuity | $4.00 | $3.33 | TheFly | Quanterix price target lowered to $4 from $8 at Canaccord |
| December 22, 2025 12:00 pm | — | Canaccord Genuity | $8.00 | $6.59 | TheFly | Quanterix price target raised to $8 from $5 at Canaccord |
| March 25, 2025 1:35 pm | Sung Ji Nam | Scotiabank | $18.00 | $7.02 | TheFly | Quanterix price target lowered to $18 from $28 at Scotiabank |
| June 11, 2024 7:54 am | Sung Niam | Scotiabank | $32.00 | $18.50 | StreetInsider | Scotiabank Reiterates Sector Outperform Rating on Quanterix Corp. (QTRX) |
| May 8, 2024 1:42 pm | Kyle Mikson | Canaccord Genuity | $25.00 | $16.51 | TheFly | Quanterix growth potential not reflected in shares, says Canaccord |
| November 10, 2022 10:12 am | — | Goldman Sachs | $13.00 | $11.72 | Benzinga | Goldman Sachs Maintains Neutral on Quanterix, Lowers Price Target to $13 |
Latest News for QTRX
Quanterix NASDAQ: QTRX CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma markets.
Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript
Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to…
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTRX.
U.S. House Trading
No House trades found for QTRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.